Pour yourself a cup of fresh coffee or chai, because I’ve got something interesting for you:
Each month I review and summarize hundreds of vitiligo-related news articles and papers for this newsletter. Frankly, most of them are too technical, too boring or simply not clear enough to share with you in an email.
But it’s still all important information. So, every now and then, I draw from all this data to create a report on a specific theme.
And my latest analysis is a succinct overview of the competitors in the biopharma pipeline, along with the clinical trial status, pharmacological action, agreements and collaborations, and stock price trajectory.
The top key players in the vitiligo market today are Incyte and Pfizer, both with active clinical trials (upcoming Phase III and current Phase II, respectively) underway. Other companies with mainly off-label products for use in vitiligo include Astellas Pharma, Bausch Health, Bristol-Myers Squibb, Celgene, Dr. Reddy’s Laboratories, Puneet Laboratories, and Sesderma.
For all the optimism surrounding vitiligo therapies from these major pharma companies, there are signs some of them are quite overblown. My biggest concern here is about patient selection criteria, therapy side-effects and frequent relapse after successful treatment. (In fact, smaller biotech startups may hold more hope for vitiligo patients and are most attractive for investors in the life sciences industry.)
The market report delves deep into all of this. It’s taken a lot of time and effort to put together. So much so that it would cost you $2,000 minimum elsewhere. But, as one of my loyal subscribers, it’s free to you.
Interested? Get ready to dig in.
The full report (UPDATED) - including analysis of 20 biotech startups with vitiligo therapeutics in the pipeline - is posted on our website, exclusively for VR Foundation friends.
But there’s no rest for the wicked, as I’m already hard at work on my next report, concerning the price tag of novel vitiligo therapies. (Spoiler alert: it won’t be cheap.)
The three largest Pharmacy Benefit Managers in the U.S. are collectively making prescription drug coverage decisions for over two-thirds of Americans. All have a general policy that they will automatically cover any FDA-approved drug that costs $100,000 or less per quality-adjusted life years (QALY). Which of the novel therapies could fit the bill? Stay tuned to find out.
CEO VR Foundation
- Is it possible to stop the progression of vitiligo?
It is true that vitiligo progression could be stopped in 4 out of 5 cases by the use of potent systemic corticosteroids - that is, oral medications. However, systemic corticost...
- What is vitiligo?
Vitiligo (pronounced vit-ill-EYE-go) is a relatively common skin disease characterized by smooth, white, painless spots or patches on various parts of the body and hairs above i...
- I have vitiligo: will my children have vitiligo, too?
Children born to parents who both have the disorder are more likely to develop vitiligo. However, most children will not get vitiligo even if one parent has it. In children wit...
Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.